Cancer Chemother Pharmacol

1. ALZAHRANI R, Alghadmi MA
   Translational applications and clinical utility of organoids in ovarian cancer: a systematic review.
   Cancer Chemother Pharmacol. 2026;96:121.
   

   >> Share

   
   

   
   Clin Cancer Res

2. KONECNY GE, Lim PC, Santin AD, Gilbert L, et al
   Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
   Clin Cancer Res. 2026 Oct 21. doi: 10.1158/1078-0432.CCR-26-0238.
   

   >> Share

   
   

   
   Gynecol Oncol

3. GERSHENSON DM
   MEK-Ing progress in low-grade serous ovarian cancer.
   Gynecol Oncol. 2026;213:A1-A3.
   

   >> Share

   
   
4. GRISHAM RN, Slomovitz B, Podder V, Sun C, et al
   Low-grade serous ovarian cancer: 2026 expert consensus report.
   Gynecol Oncol. 2026;214:144-163.
   

   >> Share

   
   
5. THORNTON S, O'Loughlin M, Nuk J, Borle K, et al
   A cross-sectional survey exploring experiences in accessing hormone replacement therapy following risk-reducing surgery for individuals with hereditary ovarian cancer risk.
   Gynecol Oncol. 2026;214:135-143.
   

   >> Share

   
   
6. WENHAM RM, Ray-Coquard I, Kristeleit R, Matei D, et al
   Farletuzumab ecteribulin, a folate receptor alpha (FRalpha) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study.
   Gynecol Oncol. 2026;213:109-119.
   

   >> Share

   
   
7. DURMUS AB, Yucel GS
   The diagnostic value of serum glucagon-like peptide-1 (GLP-1) levels in endometrial cancer among obese women.
   Gynecol Oncol. 2026;213:102-108.
   

   >> Share

   
   
8. RAFFONE A, Neola D, Tranchini A, Mele M, et al
   Molecular groups predict response to fertility-sparing treatment of endometrial carcinoma: a systematic review and metanalysis.
   Gynecol Oncol. 2026;213:25-32.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share